Key takeaways

  • Freedom Broker downgraded VolitionRx to Hold.
  • VolitionRx reports significant progress with its Nu.Q diagnostic platform, including peer-reviewed validation in sepsis and early-stage cancer detection above 95%.
  • The company expanded its Fujifilm agreement, reduced debt by over $5 million, and holds more than 70 patents for its platform.

VolitionRx (NYSE American: VNRX) develops the Nu.Q diagnostic platform. Freedom Broker downgraded VolitionRx to Hold when the stock was priced at $0.19. The shares trade at $0.19, down $0.01, or 5.56%, on volume of 3,018,250 shares.

The downgrade comes as VolitionRx reports progress across its Nu.Q product lines. Its 2026 work includes peer-reviewed validation in sepsis, early-stage cancer detection above 95% in a blinded cohort, and a government-funded sepsis program in France, as highlighted by PRNewsWire.

VolitionRx also expands its Fujifilm agreement to include cats and reduces debt by more than $5 million, as highlighted by PRNewsWire. The company is discussing licenses with more than a dozen diagnostic and liquid biopsy companies worldwide.

VolitionRx says more than 70 patents protect its platform. It aims to co-develop and license the technology in exchange for upfront payments, milestone payments and royalties. The stock’s one-year range is $0.16 to $7.80, and its market capitalization is about $2.27 million.